Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Gilead Sciences has completed its previously announced acquisition of Immunomedics, a Morris Plains, New Jersey-based clinical-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs), for approximately $21 billion. Gilead had...

Bayer has agreed to acquire Asklepios BioPharmaceutical (AskBio), a Research Triangle Park, North Carolina-based clinical-stage gene-therapy company, in a deal worth up to $4 billion ($2 billion upfront and up to $2 billion in milestone...

A roundup of news from Australia (Australian government), Canada (Roche), UK (UCB), and the US (Astellas, iota Biosciences). Australia Australian Gov’t Issues $355,000 in Funding for Clinical Trial MfgThe Australian government has provided...

Eli Lilly and Company has agreed to acquire Disarm Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company, in a $1.36-billion deal ($135 million upfront and $1.225 billion in milestones). Disarm Therapeutics is a start-up company...

A roundup of news from the US (Regeneron, Seattle Genetics). US FDA OKs Regeneron’s Ebola Drug The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals’ Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for treating...

Merck & Co. reports it will construct a new manufacturing facility in North Carolina to expand its production capacity for TICE BCG, a medicine containing live, attenuated mycobacteria, and used for treating certain forms of bladder...